Sector News

Pfizer halts production at India injectables plant after FDA again finds issues

July 18, 2018
Life sciences

Pfizer has again suspended production at a long-troubled sterile injectables plant in India that the FDA has twice before cited for manufacturing and testing issues.

The agency recently outlined problems in a highly redacted, 32-page Form 483 following an inspection of the plant in Irungattukottai, India, a facility that was cited with a Form 483 two years ago and with a warning letter in 2013.

The document includes 11 observations that outline problems with product testing and consistency and which noted that workers “manipulated test sample weights to obtain passing results” for both batches of raw materials and finished product,

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

It also says the plant was slow about investigating customer product complaints and points to complaints about a dozen batches for which inspections were not concluded five months after they were received. Seven of the 12 batches had already expired as the investigations were pending. The FDA suggests that many of the plant’s problems stem from poorly trained employees who do not understand the nature of the work they were doing.

In an emailed statement on Monday, Pfizer said it was “disappointed with the outcome” of the inspection and had already submitted a comprehensive response to the FDA.

Pfizer said it is “committed to implementing the necessary improvements and to ensuring the quality of our medicines.” It said it had “voluntarily paused production” at the Irungattukottai, India, site until its internal review and remediation process is complete.

RELATED: U.K. finds big issues with Pfizer Hospira plant in India

Pfizer bought Hospira in 2015 for $15 billion to get its biosimilars program and its large manufacturing network for generic hospital injectables. At the time of the deal, it assured investors and the FDA that it could fix the manufacturing problems that had long plagued Hospira’s manufacturing operations.

That was easier said than done. Pfizer closed or sold several plants that had accounted for many FDA concerns, but in August 2016, the plant in Irungattukottai, India, was slapped with a Form 483 after having received a warning letter three years earlier. European regulators also noted issues and pulled its manufacturing certificate at the time. The EU inspection uncovered a variety of critical issues that regulators said called into question whether the injectable products coming out of the facility were consistently sterile.

RELATED: Pfizer plant hit with warning letter has history of FDA problems

The FDA has also found big issues with a former fill-finish plant in McPherson, Kansas, that was hit with a warning letter last year. Because that plant does a lot of work for other drugmakers, its problems have spilled onto some of Pfizer’s clients, even delaying approvals of key products.

But the former Hospira unit is set to get new company oversight. In a reorganization announced last week, the New York drugmaker said that beginning next year it will divide the company into three parts rather than its current two. It put its branded drug business in charge of both biosimilars and the injectable hospital drugs, which have been the target of FDA actions. The other two units will be consumer health and a separate generics business.

By: Eric Palmer

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.